Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Raloxifene augmentation for schizophrenia spectrum disorders
NL-OMON55630Phase 3Active, not recruiting
- Sponsor
- Partner Psychiatrie
- Start
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in schizophrenia, schizoaffective disorder, schizophreniform disorder and 1 more comparing Raloxifene augmentation with Placebo augmentation (2 arms). Primary endpoints: Change in psychotic symptom severity and Change in cognition. Started Nov 2016; status: active, not recruiting.
02
Drugs
raloxifene
03
Conditions
schizophreniaschizoaffective disorderschizophreniform disorderSchizophrenia Spectrum Disorders (SSD)
Beyond the preview
Go deeper on NL-OMON55630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55630.